Company Overview

Parcell Laboratories, founded in 2008, is focused on developing novel therapeutics around our unique adult stem cell platform technology, the ELA® cell. The ELA cell was discovered by scientists affiliated with the Brigham and Women’s Hospital and Harvard Medical School who demonstrated the vast potential of the technology in regenerative medicine. ELA cells are found in various tissues throughout the body and are characterized by a specific surface marker profile that set them apart from other adult stem cells.

Parcell Laboratories wholly owned subsidiaries were established around the ELA stem cell technology to support manufacturing, archival and strategic partner relationships in the delivery of the highest quality stem cell products and services. Cellogx, Parcell Spine, and CellCure Trust are incorporated in the state of Delaware and domiciled in Natick, MA.

PureGen® Osteoprogenitor Cell Allograft, was launched in partnership with Alphatec Spine, Inc. (NYSE:ATEC) in 2010. PureGen, an allograft containing unexpanded ELA cells from live, healthy donors served as an add-on to the standard of care in surgical procedures to promote fusion in the aging or at risk spine.

Parcell Laboratories’ ELA cell technology is currently being evaluated for cartilage repair and the remediation of rhytides (wrinkles). Whether used in an autologous or allogeneic therapy, ELA cells hold promise for the regeneration of many different tissue types.

Based in Natick, MA, the Company’s state-of-the-art research, processing, storage and fulfillment facilities set the stage for the future of adult stem cells and regenerative medicine.